Compare Abbott Laboratories (ABT) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Harmony Gold Mining Co. — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Harmony Gold Mining Co. trades at $14.42 (market cap $9.60B). The key difference: Abbott Laboratories is far larger — about 17.4× Harmony Gold Mining Co.'s market cap, and Harmony Gold Mining Co. pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| ABT | HMY | |
|---|---|---|
Market Cap | $166.94B | $9.60B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $26.04 |
52-Week Low | $82.57 | $12.61 |
Enterprise Value | $193.69B | $9.93B |
Dividend Yield | 2.63% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Harmony Gold Mining (HMY) trades at $15.385, down 4.38% amid broader gold sector weakness. The stock shows strong fundamentals with 2024 revenue of $61.38B and net income of $8.59B, representing a 13.99% margin. Technical indicators signal bearish momentum with RSI at oversold levels. Recent earnings beat expectations in Q2 2025 but missed in Q4 2025, while analysts maintain a cautious stance with 70% hold ratings.
HMY presents value with attractive valuation ratios (P/E 10.42, EV/EBITDA 5.36) and robust profitability (ROE 32.32%). However, Fed rate hike concerns and gold price volatility pose near-term headwinds. The company's transition to gold-copper hybrid operations by 2028 offers long-term growth potential, though execution risks and commodity price exposure remain key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
